Elicio Therapeutics, Inc. (ELTX) Fair Value 2026

ELTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Elicio Therapeutics, Inc. (ELTX) trades at $2.84. QOC: 4.5/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
ELTX
Price
$2.84
Quality Score
4.5/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ELTX?

1 Intrinsic Value Models vs. Current Price ($2.84)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $1.55 -45.5%

All Models Active

All 1 models are displayed above.

What Is Elicio Therapeutics, Inc. (ELTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Elicio Therapeutics, Inc.'s intrinsic value is estimated at $1.55, suggesting the stock is overvalued at its current price of $2.84. With 1 out of 1 models flagging downside (-45.5% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About ELTX?

1 of 13 models are currently active for ELTX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ELTX Rank in Biotechnology?

Among 625 Biotechnology stocks, ELTX ranks #455 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Elicio Therapeutics, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ELTX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ELTX a Value Trap?

CirclFi's Value Trap algorithm assigns ELTX a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Elicio Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Elicio Therapeutics, Inc.'s fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ELTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ELTX's 1 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Elicio Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

HOWLWerewolf Therapeutics, Inc.QOC 4.5LIMNLiminatus Pharma, Inc.QOC 4.5NRXPNRx Pharmaceuticals, Inc.QOC 4.5IMNNImunon, Inc.QOC 4.5GANXGain Therapeutics, Inc.QOC 4.5GLSIGreenwich LifeSciences, Inc.QOC 4.5EVAXEvaxion A/SQOC 2.4LPCNLipocine Inc.QOC 6.1SLSSELLAS Life Sciences Group, Inc.QOC 5.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: HOWL · LIMN · NRXP · IMNN · GANX · GLSI · EVAX · LPCN · SLS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ELTX?

4 companies across all industries closest to ELTX’s Quality of Company score of 4.5/10.

AGSSAmeriguard Security Services, Inc.QOC 4.5EQSEquus Total Return, Inc.QOC 4.5SFCXSUPA Consolidated Inc.QOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AGSS · EQS · SFCX · NVDA

Where Does ELTX Sit in CirclFi's Biotechnology Rankings?

ELTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Elicio Therapeutics, Inc.’s Valuation?

What is Elicio Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Elicio Therapeutics, Inc. (ELTX). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ELTX overvalued or undervalued right now?

At $2.84, 0 of 1 active models suggest ELTX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Elicio Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.5 mean for ELTX?

Elicio Therapeutics, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ELTX?

CirclFi analyzes ELTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ELTX a value trap in 2026?

Elicio Therapeutics, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Elicio Therapeutics, Inc. (ELTX) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ELTX/ · Methodology
Primary sources for this ELTX valuation
  • Financial statements: Elicio Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001601485) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ELTX as of ; valuations recomputed .